Amgen Inc. (NASDAQ:AMGN)‘s stock had its “outperform” rating restated by equities researchers at Cowen and Company in a note issued to investors on Saturday, July 22nd. They presently have a $209.00 price target on the medical research company’s stock. Cowen and Company’s price target suggests a potential upside of 24.93% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Mizuho set a $195.00 price target on Amgen and gave the stock a “buy” rating in a research note on Saturday, May 6th. Vetr cut Amgen from a “strong-buy” rating to a “buy” rating and set a $178.82 price target on the stock. in a research note on Monday, April 3rd. BMO Capital Markets reaffirmed a “buy” rating and issued a $198.00 price target (down from $200.00) on shares of Amgen in a research note on Monday, May 22nd. Finally, ValuEngine raised Amgen from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $186.64.

Shares of Amgen (NASDAQ AMGN) traded down 0.31% during mid-day trading on Friday, reaching $167.29. The company had a trading volume of 1,741,936 shares. The firm has a market capitalization of $122.07 billion, a PE ratio of 15.24 and a beta of 1.35. Amgen has a 12-month low of $133.64 and a 12-month high of $184.21. The stock has a 50 day moving average price of $174.04 and a 200 day moving average price of $168.05.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.84 EPS. On average, equities analysts forecast that Amgen will post $12.57 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/19/cowen-and-company-reaffirms-outperform-rating-for-amgen-inc-nasdaqamgn-updated-updated-updated.html.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Norges Bank acquired a new position in Amgen during the fourth quarter valued at $1,016,913,000. Janus Henderson Group PLC boosted its position in Amgen by 3,664.7% in the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock valued at $637,139,000 after buying an additional 3,601,087 shares in the last quarter. FMR LLC boosted its position in Amgen by 4.8% in the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after buying an additional 2,587,041 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in Amgen during the fourth quarter valued at $275,209,000. Finally, Renaissance Technologies LLC boosted its position in Amgen by 40.9% in the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after buying an additional 986,700 shares in the last quarter. Hedge funds and other institutional investors own 79.12% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.